Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation (HCT): A Single Center Analysis of 613 Adult HCT Recipients Using a Modified Composite Endpoint

Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Stacey Brown, B.A., Asad Bashey, MD PhD

Blood (2016) 128 (22): 4574.

https://doi.org/10.1182/blood.V128.22.4574.4574

Published: 2016

Journal Articles

Excellent Long Term Survival Among Patients Who Are Disease-Free at One Year after Allogeneic Hematopoietic Cell Transplantation: A Single Center Analysis of 667 Consecutive Patients

Melhem Solh, MD, Asad Bashey, MD PhD, Scott R. Solomon, MD, Lawrence E. Morris, MD, Xu Zhang, Stacey Brown, B.A., H. Kent Holland, MD

Blood (2016) 128 (22): 4622.

https://doi.org/10.1182/blood.V128.22.4622.4622

Published: 2016

Journal Articles

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

Blood (2016) 128 (22): 1163.

https://doi.org/10.1182/blood.V128.22.1163.1163

Published: 2016

Journal Articles

Myeloablative Allogeneic Hematopoietic Cell Transplantation Performed without Routine Inpatient Admission: A Single Center Experience of 462 Consecutive Patients

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Jackson, Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2016) 128 (22): 661.

https://doi.org/10.1182/blood.V128.22.661.661

Published: 2016

Journal Articles

T Cell Replete HLA- Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (pTcy) Is an Effective Salvage for Patients Relapsing after a Matched Sibling or a Matched Unrelated Donor Transplantation

Melhem Solh, MD, Katelin Connor, Xu Zhang, PhD, Stacey Brown, B.A., Lawrence E. Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD, Scott R. Solomon, MD

Blood (2015) 126 (23): 1960.

https://doi.org/10.1182/blood.V126.23.1960.1960

Published: 2015

Journal Articles

Lower Use of DLI Post Relapse of Malignancy May Result in Shorter Post-Relapse Survival (PRS) in Patients Undergoing T Cell Replete Haploidentical Donor Transplantation (HIDT) Versus Matched Related (MRD) or Matched Unrelated Donor (MUD) Hematopoietic Cell Transplantation (HCT)

Melhem Solh, MD, Xu Zhang, PhD, Stacey Brown, B.A., Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Asad Bashey, MD PhD

Blood (2015) 126 (23): 1967.

https://doi.org/10.1182/blood.V126.23.1967.1967

Published: 2015

Journal Articles

Factors Predicting Gvhd Free, Relapse Free Survival (GRFS) after Allogeneic Hematopoietic Cell Transplantation; A Multivariable Analysis of 531 Allografts from a Single Center

Melhem Solh, MD, Xu Zhang, PhD, Katelin Connor, Stacey Brown, B.A., H. Kent Holland, MD, Lawrence E. Morris, MD, Scott R. Solomon, MD, Asad Bashey, MD PhD

Blood (2015) 126 (23): 2028.

https://doi.org/10.1182/blood.V126.23.2028.2028

Published: 2015

Journal Articles

Non-Inferior Survival of Black Versus White Patients and Superior Outcomes for Black Females Compared to Other Race/Gender Groups Following Allogeneic Transplantation for Hematologic Malignancy: A Single Center Multivariable Analysis of 475 Allografted Patients

Asad Bashey, MD PhD, Xu Zhang, PhD, Katelin Jackson, Stacey Brown, B.A., Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2015) 126 (23): 401.

https://doi.org/10.1182/blood.V126.23.401.401

Published: 2015

Journal Articles

Lineage Specific Chimerism Analysis Reveals That Mixed Donor T-Cell Chimerism Is Common in the Early Post-Transplant Period Following Myeloablative Allotransplants from HLA-Matched but Not HLA-Haploidentical Donors: A Multivariable Analysis of Allografted Patients from a Single Center

Asad Bashey, MD PhD, Xu Zhang, PhD, Katelin Jackson, Stacey Brown, B.A., Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2015) 126 (23): 4327.

https://doi.org/10.1182/blood.V126.23.4327.4327

Published: 2015

Journal Articles

FLAG-Idarubicin Is Superior to Cytarabine Plus Idarubicin (7+3) for Initial Treatment of Acute Myeloid Leukemia (AML): A Multivariable Analysis of Patients Treated at a Single Center

Ronald Mihelic, PharmD, BCOP, Elizabeth Dickhaus, Pharm.D., Stacey Brown, B.A., Xu Zhang, PhD, Scott R. Solomon, MD, Lawrence E. Morris, MD, Asad Bashey, MD PhD, H. Kent Holland, MD

Blood (2014) 124 (21): 3728.

https://doi.org/10.1182/blood.V124.21.3728.3728

Published: 2014

Journal Articles

Chronic GVHD Is Not Increased with the Use of PBSC Instead of Bone Marrow for T-Replete HLA-Haploidentical Transplanation Using Post-Transplant Cyclophosphamide : A Multivartiate Analysis of 116 Consecutive Transplants from a Single Center

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Connor, Lawrence E. Morris, MD, H. Kent Holland, MD, Ridgeway Michelle, RN, Scott R. Solomon, MD

Blood (2014) 124 (21): 3922.

https://doi.org/10.1182/blood.V124.21.3922.3922

Published: 2014

Journal Articles

Age Related Outcomes for Multiple Myeloma Patients Following Autologous Transplantation

Justin LaPorte, PharmD, BCOP, Stacey Brown, B.A., Xu Zhang, PhD, Asad Bashey, MD PhD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2014) 124 (21): 3968.

https://doi.org/10.1182/blood.V124.21.3968.3968

Published: 2014

Journal Articles

TBI-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors

Scott R. Solomon, MD, Connie Sizemore, PharmD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Connor, B.S., Lawrence E. Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2014) 124 (21): 426.

https://doi.org/10.1182/blood.V124.21.426.426

Published: 2014

Journal Articles

Use of the Dana-Farber/CIBMTR Disease Risk Index (DRI) to Compare Outcomes of T-Replete HLA-Haploidentical Transplants Using Post-Transplant Cyclophosphamide to Matched Sibling and Matched Unrelated Donor Transplants : A Multivariate Analysis of 498 Contemporaneous Allogeneic Transplants from a Single Center

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Connor, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2014) 124 (21): 1203.

https://doi.org/10.1182/blood.V124.21.1203.1203

Published: 2014

Journal Articles

Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in Excellent Responses and Rapid Time to Immunosuppression Discontinuation

Connie Sizemore, PharmD, Michelle Ridgeway, RN, OCN, Xu Zhang, PhD, Stacey Brown, B.A., Lawrence E. Morris, MD, Asad Bashey, MD PhD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2014) 124 (21): 2487.

https://doi.org/10.1182/blood.V124.21.2487.2487

Published: 2014

Journal Articles

Overall and Disease-Specific Outcomes Following T-Cell Replete Haploidentical Transplants Using Post-Transplant Cyclophosphamide: An Analysis Of 115 Patients Transplanted At a Single Center

Asad Bashey, MD, PhD, Xu Zhang, PhD, Zaamin Hussain, Stacey Brown, B.A., Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2013) 122 (21): 3337.

https://doi.org/10.1182/blood.V122.21.3337.3337

Published: 2013

Journal Articles

Calcineurin Inhibitor-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide and Brief-Course Sirolimus Results in Low Rates of Non-Relapse Mortality and Chronic GVHD Following Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (PBSCT)

Melissa Sanacore, PharmD, Asad Bashey, MD, PhD, Connie A. Sizemore, PharmD, H. Kent Holland, MD, Lawrence E. Morris, MD, Stacey Brown, B.A., Xu Zhang, PhD, Scott R. Solomon, MD

Blood (2013) 122 (21): 923.

https://doi.org/10.1182/blood.V122.21.923.923

Published: 2013

Journal Articles

Lineage–Specific Chimerism and Incidence of Graft-Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eighty-Nine Consecutive Patients From a Single-Center.

Amaani Hussain, Connie A. Sizemore, PharmD, Xu Zhang, PhD, Melissa Sanacore, PharmD, Stacey Brown, B.A., Karen Manion, RN, Lawrence E. Morris, Jr., MD, H. Kent Holland, MD, Scott R. Solomon, MD, Asad Bashey, MD, PhD

Blood (2012) 120 (21): 3030.

https://doi.org/10.1182/blood.V120.21.3030.3030

Published: 2012

Journal Articles

Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial

Connie A. Sizemore, PharmD, Asad Bashey, MD, PhD, Melissa Sanacore, PharmD, Karen Manion, RN, H. Kent Holland, MD, Lawrence E. Morris, MD, Stacey Brown, B.A., Xu Zhang, PhD, Scott R. Solomon, MD

Blood (2011) 118 (21): 889.

https://doi.org/10.1182/blood.V118.21.889.889

Published: 2011

NARROW

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation (HCT): A Single Center Analysis of 613 Adult HCT Recipients Using a Modified Composite Endpoint

Excellent Long Term Survival Among Patients Who Are Disease-Free at One Year after Allogeneic Hematopoietic Cell Transplantation: A Single Center Analysis of 667 Consecutive Patients

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

Myeloablative Allogeneic Hematopoietic Cell Transplantation Performed without Routine Inpatient Admission: A Single Center Experience of 462 Consecutive Patients

T Cell Replete HLA- Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (pTcy) Is an Effective Salvage for Patients Relapsing after a Matched Sibling or a Matched Unrelated Donor Transplantation

Lower Use of DLI Post Relapse of Malignancy May Result in Shorter Post-Relapse Survival (PRS) in Patients Undergoing T Cell Replete Haploidentical Donor Transplantation (HIDT) Versus Matched Related (MRD) or Matched Unrelated Donor (MUD) Hematopoietic Cell Transplantation (HCT)

Factors Predicting Gvhd Free, Relapse Free Survival (GRFS) after Allogeneic Hematopoietic Cell Transplantation; A Multivariable Analysis of 531 Allografts from a Single Center

Non-Inferior Survival of Black Versus White Patients and Superior Outcomes for Black Females Compared to Other Race/Gender Groups Following Allogeneic Transplantation for Hematologic Malignancy: A Single Center Multivariable Analysis of 475 Allografted Patients

Lineage Specific Chimerism Analysis Reveals That Mixed Donor T-Cell Chimerism Is Common in the Early Post-Transplant Period Following Myeloablative Allotransplants from HLA-Matched but Not HLA-Haploidentical Donors: A Multivariable Analysis of Allografted Patients from a Single Center

FLAG-Idarubicin Is Superior to Cytarabine Plus Idarubicin (7+3) for Initial Treatment of Acute Myeloid Leukemia (AML): A Multivariable Analysis of Patients Treated at a Single Center

Chronic GVHD Is Not Increased with the Use of PBSC Instead of Bone Marrow for T-Replete HLA-Haploidentical Transplanation Using Post-Transplant Cyclophosphamide : A Multivartiate Analysis of 116 Consecutive Transplants from a Single Center

Age Related Outcomes for Multiple Myeloma Patients Following Autologous Transplantation

TBI-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors

Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in Excellent Responses and Rapid Time to Immunosuppression Discontinuation

Overall and Disease-Specific Outcomes Following T-Cell Replete Haploidentical Transplants Using Post-Transplant Cyclophosphamide: An Analysis Of 115 Patients Transplanted At a Single Center

Calcineurin Inhibitor-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide and Brief-Course Sirolimus Results in Low Rates of Non-Relapse Mortality and Chronic GVHD Following Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (PBSCT)

Lineage–Specific Chimerism and Incidence of Graft-Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eighty-Nine Consecutive Patients From a Single-Center.

Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only